Synergistic effect of non-transmissible Sendai virus vector encoding the c-myc suppressor FUSE-binding protein-interacting repressor plus cisplatin in the treatment of malignant pleural mesothelioma

Cancer Science

Volumn 102, Issue 7, 2011, Pages 1366-1373

  Kitamura, Atsushi ^a   Matsushita, Kazuyuki ^a   Takiguchi, Yuichi ^a   Shimada, Hideaki ^b   Tada, Yuji ^a   Yamanaka, Makako ^a   Hiroshima, Kenzo ^c   Tagawa, Masatoshi ^d   Tomonaga, Takeshi ^e   Matsubara, Hisahiro ^a   Inoue, Makoto ^f   Hasegawa, Mamoru ^f   Sato, Yasunori ^g   Levens, David ^h   Tatsumi, Koichiro ^a   Nomura, Fumio ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Tokyo Women s Medical University   (Japan)

^d CHIBA CANCER CENTER   (Japan)

^e NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^f DNAVEC Corporation   (Japan)

^g CHIBA UNIVERSITY HOSPITAL   (Japan)

^h NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FUSE BINDING PROTEIN INTERACTING REPRESSOR; GREEN FLUORESCENT PROTEIN; MYC PROTEIN; REPRESSOR PROTEIN; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL IMMORTALIZATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; FUSION GENE; GENE DELETION; GENE OVEREXPRESSION; GENETIC CODE; HUMAN; HUMAN TISSUE; MALE; MALIGNANT MESOTHELIOMA; MESOTHELIUM CELL; MOUSE; NONHUMAN; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SENDAI VIRUS; SIGNAL TRANSDUCTION; SURVIVAL RATE;

ANIMALS; APOPTOSIS; CARRIER PROTEINS; CELL LINE, TUMOR; CISPLATIN; GENE THERAPY; GENETIC VECTORS; HUMANS; MALE; MESOTHELIOMA; MICE; MICE, INBRED BALB C; PLEURAL NEOPLASMS; SENDAI VIRUS; TRANSDUCTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79959280743     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.01931.x     Document Type: Article

References (29)

1. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005; 353: 1591-603.
2. Hodgson JT, McElvenny DM, Darnton AJ, Price MJ, Peto J. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 2005; 92: 587-93.
3. Ramalingam SS, Belani CP. Recent advances in the treatment of malignant pleural mesothelioma. J Thorac Oncol 2008; 3: 1056-64.
4. Tada Y, Takiguchi Y, Hiroshima K et al. Gene therapy for malignant pleural mesothelioma: present and future. Oncol Res 2008; 17: 239-46.
5. Vachani A, Moon E, Wakeam E, Albelda SM. Gene therapy for mesothelioma and lung cancer. Am J Respir Cell Mol Biol 2010; 42: 385-93.
6. Sterman DH, Recio A, Vachani A et al. Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy. Clin Cancer Res 2005; 11: 7444-53.
7. Markwell MA, Svennerholm L, Paulson JC. Specific gangliosides function as host cell receptors for Sendai virus. Proc Natl Acad Sci U S A 1981; 78: 5406-10.
8. Nagai Y. Paramyxovirus replication and pathogenesis. Reverse genetics transforms understanding. Rev Med Virol 1999; 9: 83-99.
9. Bitzer M, Armeanu S, Lauer UM, Neubert WJ. Sendai virus vectors as an emerging negative-strand RNA viral vector system. J Gene Med 2003; 5: 543-53.
10. Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 2005; 6: 635-45.
11. Ramael M, Van den Bossche J, Buysse C, Deblier I, Segers K, Van Marck E. Immunoreactivity for c-fos and c-myc protein with the monoclonal antibodies 14E10 and 6E10 in malignant mesothelioma and non-neoplastic mesothelium of the pleura. Histol Histopathol 1995; 10: 639-43.
12. Liu J, He L, Collins I et al. The FBP interacting repressor targets TFIIH to inhibit activated transcription. Mol Cell 2000; 5: 331-41.
13. Matsushita K, Tomonaga T, Shimada H et al. An essential role of alternative splicing of c-myc suppressor FUSE-binding protein-interacting repressor in carcinogenesis. Cancer Res 2006; 66: 1409-17.
14. Matsushita K, Tomonaga T, Kajiwara T et al. c-myc suppressor FBP-interacting repressor for cancer diagnosis and therapy. Front Biosci 2009; 14: 3401-8.
15. Inoue H, Iga M, Nabeta H et al. Non-transmissible Sendai virus encoding granulocyte macrophage colony-stimulating factor is a novel and potent vector system for producing autologous tumor vaccines. Cancer Sci 2008; 99: 2315-26.
16. Kimura K, Nozaki N, Enomoto T, Tanaka M, Kikuchi A. Analysis of M phase-specific phosphorylation of DNA topoisomerase II. J Biol Chem 1996; 271: 21439-45.
17. Page-McCaw PS, Amonlirdviman K, Sharp PA. PUF60: a novel U2AF65-related splicing activity. RNA 1999; 5: 1548-60.
18. Kisseleva MV, Cao L, Majerus PW. Phosphoinositide-specific inositol polyphosphate 5-phosphatase IV inhibits Akt/protein kinase B phosphorylation and leads to apoptotic cell death. J Biol Chem 2002; 277: 6266-72.
19. Tallarida RJ. Drug synergism: its detection and applications. J Pharmacol Exp Ther 2001; 298: 865-72.
20. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
21. Matsunaga N, Kanno J, Yoshimura I. A statistical method for judging synergism: application to an endocrine disruptor animal experiment. Environmetrics 2003; 14: 213-22.
22. Pandha HS, Heinemann L, Simpson GR et al. Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma. Clin Cancer Res 2009; 15: 6158-66.
23. Li Q, Yano S, Ogino H et al. The therapeutic efficacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice. Clin Cancer Res 2007; 13: 5918-25.
24. Iwadate Y, Inoue M, Saegusa T et al. Recombinant Sendai virus vector induces complete remission of established brain tumors through efficient interleukin-2 gene transfer in vaccinated rats. Clin Cancer Res 2005; 11: 3821-7.
25. Steele JP, Klabatsa A. Chemotherapy options and new advances in malignant pleural mesothelioma. Ann Oncol 2005; 16: 345-51.
26. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 2008; 14: 1291-5.
27. Drapkin R, Reardon JT, Ansari A et al. Dual role of TFIIH in DNA excision repair and in transcription by RNA polymerase II. Nature 1994; 368: 769-72.
28. Zupi G, Scarsella M, Semple SC, Mottolese M, Natali PG, Leonetti C. Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence. Clin Cancer Res 2005; 11: 1990-8.
29. Xie XK, Yang DS, Ye ZM, Tao HM. Recombinant antisense C-myc adenovirus increase in vitro sensitivity of osteosarcoma MG-63 cells to cisplatin. Cancer Invest 2006; 24: 1-8.